Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;94(s1):S203-S225.
doi: 10.3233/JAD-221298.

miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease

Emad M Elzayat  1 , Sherif A Shahien  2 , Ahmed A El-Sherif  3 , Mohamed Hosney  1
Affiliations
Review

miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease

Emad M Elzayat et al. J Alzheimers Dis. 2023.

Abstract

Alzheimer's disease (AD) is a cumulative progressive neurodegenerative disease characterized mainly by impairment in cognitive functions accompanied by memory loss, disturbance in behavior and personality, and difficulties in learning. Although the main causes of AD pathogenesis are not fully understood yet, amyloid-β peptides and tau proteins are supposed to be responsible for AD onset and pathogenesis. Various demographic, genetic, and environmental risk factors are involved in AD onset and pathogenesis such as age, gender, several genes, lipids, malnutrition, and poor diet. Significant changes were observed in microRNA (miRNA) levels between normal and AD cases giving hope for a diagnostic procedure for AD through a simple blood test. As yet, only two classes of AD therapeutic drugs are approved by FDA. They are classified as acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists (NMDA). Unfortunately, they can only treat the symptoms but cannot cure AD or stop its progression. New therapeutic approaches were developed for AD treatment including acitretin due to its ability to cross blood-brain barrier in the brain of rats and mice and induce the expression of ADAM 10 gene, the α-secretase of human amyloid-β protein precursor, stimulating the non-amyloidogenic pathway for amyloid-β protein precursor processing resulting in amyloid-β reduction. Also stem cells may have a crucial role in AD treatment as they can improve cognitive functions and memory in AD rats through regeneration of damaged neurons. This review spotlights on promising diagnostic techniques such as miRNAs and therapeutic approaches such as acitretin and/or stem cells keeping in consideration AD pathogenesis, stages, symptoms, and risk factors.

Keywords: Acitretin; Alzheimer’s disease; amyloid-β peptide; miRNA; pathogenesis; risk factors; stem cells; tau proteins.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Figures

Fig. 1
Fig. 1
AβPP splicing in non-amyloidogenic and amyloidogenic pathways.
Fig. 2
Fig. 2
Factors contribute to AD pathogenesis and development.
See this image and copyright information in PMC

References

    1. World Health Organization, 2021. Key facts on dementia. https://www.who.int/news-room/fact-sheets/detail/dementia, Last updated September 20, 2021, Accessed on October 6, 2021.
    1. Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314, 777–781. - PubMed
    1. Gao Y, Tan L, Yu JT, Tan L (2018) Tau in Alzheimer’s disease: Mechanisms and therapeutic strategies. Curr Alzheimer Res 15, 283–300. - PubMed
    1. Ashrafian H, Zadeh EH, Khan RH (2021) Review on Alzheimer’s disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol 167, 382–394. - PubMed
    1. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV (2012) Alzheimer’s disease. Subcell Biochem 65, 329–352. - PubMed

MeSH terms